Targeted Treatment for BPDCN

In this segment, Dr Luskin explains how the introduction of targeted therapy has fundamentally altered treatment goals for patients newly diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). She discusses how management has shifted from short-term disease control to achieving deep, durable remissions that can enable longer-term strategies such as allogeneic stem cell transplantation. Drawing on outcomes from registration studies and subsequent analyses, Dr Luskin highlights long-term response and survival data relevant to community oncologists and describes how these findings are reflected in current guideline-based treatment frameworks. The discussion also introduces practical considerations related to treatment duration and dosing, including how early assessment of response may inform decisions to hold tagraxofusp therapy, even after limited exposure during an initial cycle. These concepts are positioned within the broader BPDCN treatment approach, emphasizing thoughtful balancing of efficacy and safety without detailing specific management protocols.